Bronchiolitis News and Research

RSS

Study finds ginseng can help prevent, treat influenza and RSV infection

Ginseng can help treat and prevent influenza and respiratory syncytial virus (RSV), a respiratory virus that infects the lungs and breathing passages, according to research findings by a scientist in Georgia State University's new Institute for Biomedical Sciences.

22 Apr 2014

Study reports benefits of implementing bronchiolitis guidelines at Children's Medical Center Dallas

Bronchiolitis, the number-one cause of infant hospitalizations nationally, was the focus of a multidisciplinary effort by physicians and clinicians at Children's Medical Center Dallas to establish and implement clinical practice guidelines (CPGs) aimed at streamlining care and reducing unnecessary tests and therapies.

29 Mar 2014

Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for "proliferating infantile hemangioma requiring systemic therapy".

18 Mar 2014

Cord blood vitamin D linked to pediatric RTI risk

South Korean researchers say that encouraging pregnant women to spend more time outdoors or to increase their vitamin D supplementation may reduce the number of respiratory tract infections in their infants.

13 Jan 2014

AIT initiates Phase II clinical trial of NOxCureCF for patients with cystic fibrosis

Advanced Inhalation Therapies, an Israeli drug development company, announced today that it has begun enrollment in Israel for a multicenter, open label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis.

8 Jan 2014

Overweight children face increased risk of asthma

Overweight and obesity are significant risk factors for reduced lung function in school-aged children with a history of early childhood wheezing, according to a study carried out at the University of Eastern Finland. The results also showed that the use of inhaled corticosteroids for asthma in childhood may result in reduced bone mineral density in early teenage years.

2 Jan 2014

Duration of common pediatric respiratory infections estimated

An international research team has systematically reviewed the literature to formulate up-to-date estimates of the duration of common childhood respiratory tract infections.

24 Dec 2013

GSK's FluLaval Quadrivalent vaccine effective in reducing flu cases in children

GlaxoSmithKline plc announced today that a peer-reviewed study issued online by the New England Journal of Medicine has reported that GSK's FluLaval® Quadrivalent reduced flu cases among children ages 3-8 by 55.4% overall and lowered the risk of developing moderate-to-serious flu illness by 73.1%.

12 Dec 2013

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.

2 Dec 2013

Scientists identify genetic signature of respiratory syncytial virus

Scientists have identified the genetic signature of respiratory syncytial virus, the leading cause of infant hospitalizations around the world. The work is a key step toward a better understanding of the immune response to RSV, which will aid the development of a vaccine and a tool that could allow physicians to determine the severity of the infection when symptoms first develop. The study, from a team at The Research Institute at Nationwide Children's Hospital, was published this week in PLOS Medicine.

15 Nov 2013

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Pfizer Inc. (NYSE:PFE) announced today that the European Commission approved updates to the Summary of Product Characteristics (SmPC) for the company's pneumococcal conjugate vaccine Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), regarding its use in certain populations at high risk of pneumococcal disease.

18 Oct 2013

Researchers outline recommendations to lower costs and lead to better care for patients

Medical organizations are participating in a campaign to help clinicians and patients avoid wasteful and sometimes harmful medical interventions. Recently, experts in pediatric and adult health from diverse geographic locations of the United States and from a mix of academic and non- academic settings shared their experiences, consulted their colleagues, and analyzed numerous studies in the medical literature to determine the top recommendations for improving healthcare value.

20 Aug 2013

Ablynx initiates additional Phase I studies with anti-RSV Nanobody ALX-0171

Activaero GmbH, the therapeutic area specialist for respiratory diseases focusing on novel, pharmacoeconomically meaningful treatment solutions, today announced that its partner Ablynx NV has initiated additional Phase I studies with its anti-RSV Nanobody ALX-0171 using Activaero's FAVORITE inhalation approach.

18 Jul 2013

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Pfizer Inc. announced today the company's pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), received European approval for an expanded indication to include adults aged 18 to 49 years for active immunization for the prevention of invasive disease caused by vaccine-type Streptococcus pneumoniae (S. pneumoniae).

10 Jul 2013

New procedure to treat acid reflux can prevent chronic rejection in lung transplant patients

A Loyola University Medical Center study suggests that a procedure to treat acid reflux could help prevent chronic rejection in lung transplant patients.

30 Jun 2013

Smoke exposure puts infants with respiratory infections at risk for longer hospital stays

More evidence has surfaced that supports the war on smoking, especially if smokers have an infant in their household. A study published today in the June issue of Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI), found that infants with a family history of allergic disease with lower respiratory tract infections, who are exposed to secondhand smoke are at risk for longer hospital stays.

5 Jun 2013

Exposure to air pollution during prenatal period is associated with increased risk of respiratory infection in children

Living near a major roadway during the prenatal period is associated with an increased risk of respiratory infection developing in children by the age of 3, according to a new study from researchers in Boston.

21 May 2013

Childhood respiratory infections rather than analgesics usage linked to risk for asthma

A new study conducted by Boston researchers reports that the link between asthma and early childhood use of acetaminophen or ibuprofen may be driven by underlying respiratory infections that prompt the use of these analgesics, rather than the drugs themselves.

21 May 2013

Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

Pfizer Inc. presented today the results from a Phase 3 study investigating immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 18 to 49 years of age.

From Pfizer, Inc. 29 Apr 2013

Newly characterized adenoviruses can cause severe human infections

The ongoing dance between a virus and its host distinctly shapes how the virus evolves. While human adenoviruses typically cause mild infections, recent reports have described newly characterized adenoviruses that can cause severe, sometime fatal, human infections.

12 Apr 2013